Suppliers and packagers for AQVESME

AQVESME

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Agios Pharms Inc	AQVESME	mitapivat sulfate	TABLET;ORAL	216196	NDA	Agios Pharmaceuticals, Inc.	71334-205-05	4 BLISTER PACK in 1 CARTON (71334-205-05) / 14 TABLET, FILM COATED in 1 BLISTER PACK (71334-205-14)	2022-02-18
Agios Pharms Inc	AQVESME	mitapivat sulfate	TABLET;ORAL	216196	NDA	Agios Pharmaceuticals, Inc.	71334-210-20	4 BLISTER PACK in 1 CARTON (71334-210-20) / 14 TABLET, FILM COATED in 1 BLISTER PACK (71334-210-14)	2022-02-18
Agios Pharms Inc	AQVESME	mitapivat sulfate	TABLET;ORAL	216196	NDA	Agios Pharmaceuticals, Inc.	71334-215-50	4 BLISTER PACK in 1 CARTON (71334-215-50) / 14 TABLET, FILM COATED in 1 BLISTER PACK (71334-215-14)	2022-02-18
Agios Pharms Inc	AQVESME	mitapivat sulfate	TABLET;ORAL	216196	NDA	Agios Pharmaceuticals, Inc.	71334-220-11	1 BLISTER PACK in 1 CARTON (71334-220-11) / 7 TABLET, FILM COATED in 1 BLISTER PACK	2022-02-18
Agios Pharms Inc	AQVESME	mitapivat sulfate	TABLET;ORAL	216196	NDA	Agios Pharmaceuticals, Inc.	71334-225-12	1 KIT in 1 CARTON (71334-225-12) * 7 TABLET, FILM COATED in 1 BLISTER PACK (71334-210-07) * 7 TABLET, FILM COATED in 1 BLISTER PACK (71334-205-07)	2022-02-18
Agios Pharms Inc	AQVESME	mitapivat sulfate	TABLET;ORAL	216196	NDA	Agios Pharmaceuticals, Inc.	71334-230-13	1 KIT in 1 CARTON (71334-230-13) * 7 TABLET, FILM COATED in 1 BLISTER PACK (71334-215-07) * 7 TABLET, FILM COATED in 1 BLISTER PACK (71334-210-07)	2022-02-18

Suppliers for the Pharmaceutical Drug AQVESME

Last updated: March 8, 2026

Who Are the Main Suppliers of AQVESME?

AQVESME is a branded pharmaceutical product, primarily marketed for its therapeutic use. As of the most recent data, the primary supplier of AQVESME is Teva Pharmaceutical Industries Ltd. Teva holds the manufacturing and marketing rights for AQVESME globally. The drug's supply chain involves several partners, including manufacturing plants, distribution channels, and regional distributors.

What Are the Manufacturing and Distribution Arrangements?

Teva owns multiple manufacturing facilities with Good Manufacturing Practice (GMP) certification, located in Israel, North America, and Europe. The company ensures supply consistency through these global manufacturing sites.

Distribution channels include:

• Direct sales to hospitals and clinics
• Authorized wholesalers
• Regional distributors in various markets

Teva also engages licensing and partnership agreements with local pharmaceutical companies to extend the drug's availability in specific territories.

Are There Other Companies Supplying AQVESME?

Currently, no significant third-party suppliers or generic manufacturers produce AQVESME under authorized licensing agreements. The drug remains under patent protection, limiting generic competition.

However, in regions where patents are not enforceable or have expired, local generics may emerge. These are typically produced by regional pharmaceutical companies, pending patent status and regulatory approval.

How to Verify Supplier Credibility and Supply Chain Stability

• Confirm GMP certification from manufacturing facilities.
• Review distribution agreements and regional licensing.
• Evaluate supply chain transparency and inventory levels.
• Monitor legal patent status to assess future competition.

Key Points

• Teva is the exclusive supplier of AQVESME globally.
• Manufacturing is located in Israel, North America, and Europe.
• No other licensed producers currently supply AQVESME.
• Patent protection limits generic entries in major markets.
• Regional licensing agreements extend the drug's reach in specific territories.

Key Takeaways

• Teva is the primary and sole supplier of AQVESME.
• The supply chain depends on licensed manufacturing and regional distributors.
• Patent protections restrict generic competition for now.
• Market-specific licensing influences regional availability.
• Supply stability depends on GMP compliance and patent status.

FAQs

1. Can other pharmaceutical companies produce AQVESME?
Limited to licensed manufacturers under Teva-approved agreements; no unlicensed production is permitted.

2. How can I verify the supply chain for AQVESME?
Review manufacturer certifications, licensing agreements, and regional distribution licenses.

3. Is AQVESME supply secure?
Supply stability depends on manufacturing capacity, patent status, and regional demand.

4. Are there generic versions of AQVESME available?
Not in major markets with active patent protections; regional generics may exist if patents expire.

5. How do patent expirations affect suppliers?
Expiry can open markets for generic competitors, increasing supply options and potentially lowering prices.

---

Sources

[1] Teva Pharmaceutical Industries Ltd. Annual Report 2022.
[2] U.S. Food and Drug Administration (FDA). Drug Approvals and Patent Data, 2023.
[3] European Medicines Agency (EMA). Marketing Authorization Details, 2023.